Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 42Neoplasms 14Carcinoma, Hepatocellular 9Gastrointestinal Stromal Tumors 7Liver Neoplasms 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Colonic Neoplasms 3Carcinoma, Renal Cell 3Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Neoplasm Metastasis 2Lung Neoplasms 2Glioblastoma 2Esophageal Squamous Cell Carcinoma 2Astrocytoma 2Advanced Cancer 2Wilms Tumor 1Uterine Cervical Neoplasms 1Unresectable Locally Advanced or Metastatic Solid Tumors 1Stomach Neoplasms 1Spinocerebellar Degenerations 1Solid Malignant Tumors 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Renal Insufficiency 1Rectal Neoplasms 1Physician Education 1Pancreatic Neoplasms 1Neuroblastoma 1Melanoma 1

Interventions

regorafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Solid Malignant Tumors × regorafenib × Clear all
NCT06246643 2026-05-19

A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies

Bayer

Phase 2 Active not recruiting
13 enrolled

Solid Malignant Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡